Raymond James initiated coverage of Ardelyx Inc (NASDAQ: ARDX), noting the company's two early-stage launches underway for the same molecule with differentiated pricing:
Operator: Good day, ladies and gentlemen, and welcome to CymaBay’s Third Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Operator: Welcome to the Viking Therapeutics Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.